Table of Contents
ISRN Obstetrics and Gynecology
Volume 2011, Article ID 719675, 8 pages
http://dx.doi.org/10.5402/2011/719675
Research Article

Interpretation of Controversial Teratogenic Findings of Drugs Such As Phenobarbital

1Foundation for the Community Control of Hereditary Diseases, Budapest 1026, Hungary
2Second Department of Obstetrics and Gynecology, School of Medicine, Semmelweis University, Budapest 1085, Hungary

Received 16 April 2011; Accepted 21 June 2011

Academic Editor: H. C. Wallenburg

Copyright © 2011 Andrew E. Czeizel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Hauptmann, “Luminal bei epilepsie,” Münchener Medizinische Wochenschrift, vol. 59, pp. 1907–1908, 1912. View at Google Scholar
  2. M. P. De Carolis, C. Romagnoli, S. Frezza et al., “Placental transfer of phenobarbital: what is new?” Developmental Pharmacology and Therapeutics, vol. 19, no. 1, pp. 19–26, 1992. View at Google Scholar · View at Scopus
  3. O. P. Heinonen, D. Slone, and S. Shapiro, Birth Defects and Drugs in Pregnancy, John Wright-PSG, Littleton, Mass, USA, 1977.
  4. T. H. Shepard and R. J. Lemire, Catalog of Teratogenic Agents, Johns Hopkins University Press, Baltimore, Md, USA, 11th edition, 2004.
  5. G. G. Briggs, R. K. Freeman, and S. J. Yaffe, Drugs in Pregnancy and Lactation, Lippincott Williams and Wilkins, Philadelphia, Pa, USA, 7th edition, 2005.
  6. FDA: Food and Drug Administration, “Fetal risk summary,” Federal Register, vol. 44, pp. 37434–37467, 1980. View at Google Scholar
  7. D. Kjær, E. Horvath-Puhó, J. Christensen et al., “Use of phenytoin, phenobarbital, or diazepam during pregnancy and risk of congenital abnormalities: a case-time-control study,” Pharmacoepidemiology and Drug Safety, vol. 16, no. 2, pp. 181–188, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Timmermann, N. Ács, F. Bánhidy, and A. E. Czeizel, “Congenital abnormalities of 88 children born to mothers who attempted suicide with phenobarbital during pregnany: the use of a disaster epidemiological model for the evaluation of drug teratogenicity,” Pharmacoepidemiology and Drug Safety, vol. 18, no. 9, pp. 815–825, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. A. E. Czeizel, “The estimation of human teratogenic/fetotoxic risk of exposures to drugs on the basis of Hungarian experience: a critical evaluation of clinical and epidemiological models of human teratology,” Expert Opinion on Drug Safety, vol. 8, no. 3, pp. 283–303, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. A. E. Czeizel, M. Rockenbauer, C. Siffel, and E. Varga, “Description and mission evaluation of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996,” Teratology, vol. 63, no. 5, pp. 176–185, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. A. E. Czeizel, “First 25 years of the Hungarian Congenital Abnormality Registry,” Teratology, vol. 55, no. 5, pp. 299–305, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. A. E. Czeizel, Z. Intody, and B. Modell, “What proportion of congenital abnormalities can be prevented?” British Medical Journal, vol. 306, no. 6876, pp. 499–503, 1993. View at Google Scholar · View at Scopus
  13. A. E. Czeizel, D. Petik, and P. Vargha, “Validation studies of drug exposures in pregnant women,” Pharmacoepidemiology and Drug Safety, vol. 12, no. 5, pp. 409–416, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. A. E. Czeizel and P. Vargha, “Periconceptional folic acid/multivitamin supplementation and twin pregnancy,” American Journal of Obstetrics and Gynecology, vol. 191, no. 3, pp. 790–794, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Ács, F. Bánhidy, E. Puhó, and A. E. Czeizel, “Maternal influenza during pregnancy and risk of congenital abnormalities in offspring,” Birth Defects Research Part A, vol. 73, no. 12, pp. 989–996, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. A. E. Czeizel and I. Dudás, “Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation,” New England Journal of Medicine, vol. 327, no. 26, pp. 1832–1835, 1992. View at Google Scholar · View at Scopus
  17. A. E. Czeizel, “Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation,” American Journal of Medical Genetics, vol. 62, no. 2, pp. 179–183, 1996. View at Publisher · View at Google Scholar · View at Scopus
  18. A. E. Czeizel, M. Dobó, and P. Vargha, “Hungarian cohort-controlled trial of periconceptional multivitamin supplementation shows a reduction in certain congenital abnormalities,” Birth Defects Research Part A, vol. 70, no. 11, pp. 853–861, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. A. E. Czeizel, “Periconceptional folic acid and multivitamin supplementation for the prevention of neural tube defects and other congenital abnormalities,” Birth Defects Research Part A, vol. 85, no. 4, pp. 260–268, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. L. D. Botto, R. S. Olney, and J. D. Erickson, “Vitamin supplements and the risk for congenital anomalies other than neural tube defects,” American Journal of Medical Genetics, vol. 125, no. 1, pp. 12–21, 2004. View at Google Scholar · View at Scopus
  21. E. Puhó, J. Métneki, and A. E. Czeizel, “Maternal employment status and isolated orofacial clefts in Hungary,” Central European Journal of Public Health, vol. 13, no. 3, pp. 144–148, 2005. View at Google Scholar · View at Scopus
  22. J. P. Shaffer, “Multiple hypothesis testing,” Annual Review of Psychology, vol. 46, no. 1, pp. 561–584, 1995. View at Google Scholar · View at Scopus
  23. A. E. Czeizel and F. Bánhidy, “Critical evaluation of antiepileptic drugs in epileptic pregnant women—hungarian experiences,” The Open Drug Safety Journal, vol. 1, article 24, 2010. View at Google Scholar
  24. K. L. Jones, K. A. Johnson, and C. C. Chamber, “Pregnancy outcome in women treated with phenobarbital monotherapy,” Teratology, vol. 45, pp. 452–453, 1992. View at Google Scholar
  25. J. C. Thakker, S. S. Kothari, C. T. Deshmukh et al., “Hypoplasia of nails and phalanges: a teratogenic manifestation of phenobarbitone,” Indian Pediatrics, vol. 28, no. 1, pp. 73–75, 1991. View at Google Scholar · View at Scopus
  26. C. Arpino, S. Brescianini, E. Robert et al., “Teratogenic effects of antiepileptic drugs: use of an international database on Malformations and Drug Exposure (MADRE),” Epilepsia, vol. 41, no. 11, pp. 1436–1443, 2000. View at Google Scholar · View at Scopus
  27. J. Fedrick, “Epilepsy and pregnancy: a report from the Oxford record linkage study,” British Medical Journal, vol. 2, pp. 442–448, 1973. View at Google Scholar · View at Scopus
  28. M. Bethenod and A. Frederich, “Les enfants des antiepileptiques,” Pediatrie, vol. 30, pp. 227–248, 1975. View at Google Scholar
  29. E. Robert, E. Lofkvist, F. Mauguiere, and J. M. Robert, “Evaluation of drug therapy and teratogenic risk in a Rhone-Alpes district population of pregnant epileptic women,” European Neurology, vol. 25, no. 6, pp. 436–443, 1986. View at Google Scholar · View at Scopus
  30. R. Canger, D. Battino, M. P. Canevini et al., “Malformations in offspring of women with epilepsy: a prospective study,” Epilepsia, vol. 40, no. 9, pp. 1231–1236, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. Rosa F. FDA personal communication, G. G. cit Briggs, R. K. Freeman, and S. J. Yaffe, Drugs in Pregnancy and Lactation, Lippincott Williams and Wilkins, Philadelphia, Pa, USA, 7th edition, 2005.
  32. L. Milkovich and B. J. Van Den Berg, “Effects of prenatal meprobamate and chlordiazepoxide hydrochloride on human embryonic and fetal development,” New England Journal of Medicine, vol. 291, no. 24, pp. 1268–1271, 1974. View at Google Scholar · View at Scopus
  33. S. Shapiro, D. Slone, and S. C. Hartz, “Anticonvulsants and parental epilepsy in the development of birth defects,” Lancet, vol. 1, no. 7954, pp. 272–275, 1976. View at Google Scholar · View at Scopus
  34. H. P. Sorensen, Hypospadias with Special Reference to Aetiology, Munksgaard, Copenhagen, Danmark, 1953.
  35. A. Czeizel, J. Toth, and E. Erodi, “Aetiological studies of hypospadias in Hungary,” Human Heredity, vol. 29, no. 3, pp. 166–171, 1979. View at Google Scholar · View at Scopus
  36. B. Kallen, R. Bertollini, and E. Castilla, “A joint international study on the epidemiology of hypospadias,” Acta Paediatrica Scandinavica, vol. 75, no. 324, pp. 1–52, 1986. View at Google Scholar · View at Scopus
  37. A. E. Czeizel, J. Gidai, D. Petik, G. Timmermann, and E. Puhó, “Self-poisoning during pregnancy as a model for teratogenic risk estimation of drugs,” Toxicology and Industrial Health, vol. 24, no. 1-2, pp. 11–28, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. L. B. Holmes, E. A. Harvey, B. A. Coull et al., “The teratogenicity of anticonvulsant drugs,” New England Journal of Medicine, vol. 344, no. 15, pp. 1132–1138, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Rockenbauer, J. Olsen, A. E. Czeizel, L. Pedersen, and H. T. Sørensen, “Recall bias in a case-control surveillance system on the use of medicine during pregnancy,” Epidemiology, vol. 12, no. 4, pp. 461–466, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. A. E. Czeizel, D. Petik, and E. Puho, “Smoking and alcohol drinking during pregnancy. The reliability of retrospective maternal self-reported information,” Central European Journal of Public Health, vol. 12, no. 4, pp. 179–183, 2004. View at Google Scholar · View at Scopus